



The Greater Glasgow and Clyde

Paediatric Formulary

October 2019

© COPYRIGHT 2019
GREATER GLASGOW AND CLYDE NHS BOARD

ALL RIGHTS RESERVED. NO PART OF THIS PUBLICATION MAY BE REPRODUCED, STORED IN A RETRIEVAL SYSTEM, OR TRANSMITTED, IN ANY FORM OR BY ANY MEANS, ELECTRONIC, MECHANICAL, PHOTOCOPYING, RECORDING OR OTHERWISE, WITHOUT THE PRIOR PERMISSION OF GREATER GLASGOW & CLYDE NHS BOARD.

CONTENTS

1. GASTRO-INTESTINAL SYSTEM.....	3
2. CARDIOVASCULAR SYSTEM	7
3. RESPIRATORY SYSTEM	12
4. CENTRAL NERVOUS SYSTEM	15
5. INFECTIONS	21
6. ENDOCRINE SYSTEM.....	26
7. OBSTETRICS, GYNAECOLOGY, AND URINARY-TRACT DISORDERS.....	29
8. MALIGNANT DISEASE AND IMMUNOSUPPRESSION	30
9. NUTRITION AND BLOOD.....	33
10. MUSCULOSKELETAL AND JOINT DISEASES	38
11. EYE.....	41
12. EAR, NOSE, AND OROPHARYNX.....	43
13. SKIN.....	45
14. IMMUNOLOGICAL PRODUCTS AND VACCINES	49
15. ANAESTHESIA.....	50
APPENDIX 1: EMERGENCY TREATMENT OF POISONING.....	53

Key to abbreviations

O	Licensed preparation being used for an unlicensed indication
P	Preparation is only included in the Paediatric Formulary and is not included in the GGC Adult Formulary
SP	Available as an unlicensed or special preparation

1. GASTRO-INTESTINAL SYSTEM

1.1. DYSPEPSIA AND GASTRO-OESOPHAGEAL REFLUX DISEASE

1.1.1. Antacids and simeticone

CO-MAGALDROX

195/220 Suspension.

Brands include Maalox® and Mucogel®

1.1.2. Compound alginates preparations

GAVISCON® INFANT

1 dose is equivalent to half a dual sachet

PEPTAC®

Suspension

1.2. ANTISPASMODICS AND OTHER DRUGS ALTERING GUT MOTILITY

DOMPERIDONE

10mg tablets

10mg/5ml suspension

HYOSCINE BUTYLBROMIDE (BUSCOPAN®)

10mg tablets

20mg/1ml injection

SIMETICONE (INFACOL®)

40mg/ml liquid

METOCLOPRAMIDE

10mg tablets

5mg/5ml syrup

10mg/2ml injection

- Metoclopramide should only be prescribed for short-term use (up to 5 days)
- It should not be used in children below 1 year of age
- It should only be used in children over 1 year as second-choice treatment for prevention of delayed nausea and vomiting after chemotherapy and for post-operative nausea and vomiting

PEPPERMINT WATER^{SP}

1.3. ANTISECRETORY DRUGS AND MUCOSAL PROTECTANTS

1.3.1. H₂-Receptor antagonists

RANITIDINE

150mg tablets

75mg/5ml syrup

50mg/2ml injection

1.3.2. Selective antimuscarinics

GLYCOPYRRONIUM

400micrograms/ml oral solution

Restricted to specialist initiation for the symptomatic treatment of severe sialorrhoea (chronic pathological drooling) in children and adolescents aged 3 years and older with chronic neurological disorders.

1.3.3. Chelates and complexes

SUCRALFATE

1g/5ml suspension

1g tablets

1.3.4. Prostaglandin analogues

No preparations are included in the Formulary

1.3.5. Proton pump inhibitors

Care should be taken when administering proton pump inhibitors through feeding tubes. Discuss with your relevant pharmacy department.

OMEPRAZOLE

10mg capsules, 20mg capsules, dispersible tablets

40mg injection and infusion

LANSOPRAZOLE

15mg capsules, 30mg capsules, orodispersible tablets (FasTabs®)

Key to abbreviations

- O Licensed preparation being used for an unlicensed indication
 P Preparation is only included in the Paediatric Formulary and is not included in the GGC Adult Formulary
 SP Available as an unlicensed or special preparation

1.4. ACUTE DIARRHOEA

1.4.1. Adsorbents and bulk-forming drugs
No preparations are included in the Formulary

1.4.2. Antimotility drugs

LOPERAMIDE

2mg capsules
1mg/5ml syrup

1.5. CHRONIC BOWEL DISORDERS

1.5.1. Aminosalicylates

SULFASALAZINE

500mg tablets
250mg/5ml suspension

MESALAZINE

Pentasa® 500mg modified-release tablets
Pentasa® 1g modified-release granules
Pentasa® 1g/100ml retention enema
Salofalk® 500mg modified-release granules
These preparations should be prescribed by brand name

OLSALAZINE

250mg capsules

1.5.2. Corticosteroids

PREDNISOLONE

Oral preparations: See 6.3.2
20mg in 100ml enema (Predenema®)

1.5.3. Drugs affecting the immune response

ADALIMUMAB

40mg/0.8ml pre-filled injection.

Restricted to specialist use in paediatric gastroenterology for the treatment of severe active Crohn's disease in paediatric patients (6 to 17 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy, a corticosteroid, and an immunomodulator, or who are intolerant to or have contraindications for such therapies.

INFLIXIMAB

100mg injection for infusion

Restricted to use in:

- severe refractory or fistulating Crohn's disease where therapy with other immunodulating drugs has failed or is not tolerated.
- severely active ulcerative colitis in children and adolescents aged 6 to 17 years who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine or azathioprine, or who are intolerant to or have medical contraindications for such therapies. It is restricted to specialist use as an alternative to ciclosporin in patients with acute, severe paediatric ulcerative colitis (rescue therapy) who are steroid refractory.

METHOTREXATE

2.5mg, 10mg tablets
5mg/2ml, 1000mg/10ml, 2000mg injection

When dispensing is to be carried out in primary care, the 2.5mg strength tablet should be used where possible.

AZATHIOPRINE

See section 8.2.1

CICLOSPORIN

See section 8.2.1

1.6. LAXATIVES

1.6.1. Bulk-forming laxatives
No preparations are included in the Formulary

1.6.2. Stimulant laxatives

BISACODYL

5mg tablets
5mg, 10mg suppositories

Key to abbreviations

- O Licensed preparation being used for an unlicensed indication
P Preparation is only included in the Paediatric Formulary and is not included in the GGC Adult Formulary
SP Available as an unlicensed or special preparation

DOCUSATE SODIUM

12.5mg/5ml paediatric syrup

50mg/5ml syrup

SENNA

7.5mg tablets

7.5mg/5ml syrup

GLYCEROL (GLYCERIN)

1g, 2g, 4g suppositories

SODIUM PICOSULFATE

5mg/5ml elixir

1.6.3. Faecal softeners

ARACHIS OIL ENEMA

130ml enema

1.6.4. Osmotic laxatives

LACTULOSE

Liquid

LAXIDO PAEDIATRIC®

Sachets

Licensed for children aged 2 to 11 years.

LAXIDO ORANGE®

Sachets

Licensed for children aged 12 years and above.

MOVICOL® PAEDIATRIC

Sachets

PHOSPHATE ENEMA®

128ml enema

MICROLAX MICRO-ENEMA®

5ml enema

1.6.5. Bowel cleansing solutions

KLEAN-PREP®

Sachets

SODIUM PICOSULFATE

Picolax® Sachets

1.7. LOCAL PREPARATIONS FOR ANAL AND RECTAL DISORDERS

1.7.1. Soothing anal and rectal preparations

ANUSOL®

Cream and suppositories

1.7.2. Compound anal and rectal preparations with corticosteroids

No preparations are included in the Formulary

1.7.3. Rectal sclerosants

OILY PHENOL INJECTION BP

1.7.4. Management of anal fissures

No preparations are included in the Formulary

1.8. STOMA AND ENTERAL FEEDING TUBES

See British National Formulary for Children

1.9. DRUGS AFFECTING INTESTINAL SECRETIONS**1.9.1. Drugs affecting biliary composition and flow****URSODEOXYCHOLIC ACID^o**

150mg tablets

250mg capsules

250mg/5ml suspension

1.9.2. Bile acid sequestrants**COLESTYRAMINE (CHOLESTYRAMINE)**

4g sachets

1.9.3. Aprotinin

See section 2.11

1.9.4. Pancreatin**CREON[®]**

10,000 unit and 25,000 unit capsules

CREON[®] MICRO

Restricted to use in young cystic fibrosis sufferers who are unable to swallow capsules.

1.10. DRUGS FOR SHORT BOWEL SYNDROME**TEDUGLUTIDE**

Subcutaneous injection

Restricted to specialist use only. Teduglutide should only be initiated in paediatric patients aged 1 to 17 years.

2. CARDIOVASCULAR SYSTEM

2.1. POSITIVE INOTROPIC DRUGS

2.1.1. Cardiac glycosides

DIGOXIN

- 62.5microgram tablets
- 250microgram/5ml elixir
- 500microgram/2ml injection

2.1.2. Phosphodiesterase inhibitors

ENOXIMONE^O

- 100mg/20ml injection

MILRINONE^O

- 10mg/10ml injection

2.2. DIURETICS

2.2.1. Thiazides and related diuretics

CHLOROTHIAZIDE^{SP}

- 250mg/5ml suspension

METOLAZONE

- 5mg tablets

2.2.2. Loop diuretics

FUROSEMIDE (FRUSEMIDE)

- 20mg, 40mg tablets
- 4mg/ml liquid
- 20mg/2ml, 50mg/5ml and 250mg/25ml injection

2.2.3. Potassium-sparing diuretics and aldosterone antagonists

AMILORIDE

- 5mg tablets
- 5mg/5ml oral solution

POTASSIUM CANRENOATE^{SP}

- 200mg injection

SPIRONOLACTONE

- 25mg tablets
- 50mg/5ml suspension^{SP}

2.2.4. Potassium-sparing diuretics with other diuretics

- No preparations are included in the Formulary

2.2.5. Osmotic diuretics

MANNITOL

- 10% and 20% infusion (500ml)

2.2.6. Mercurial diuretics

- No preparations are included in the Formulary

2.2.7. carbonic anhydrase inhibitors

ACETAZOLAMIDE^O

- 250mg tablets
- Though this is a weak diuretic, it is more often used for glaucoma (see 11.6), epilepsy and raised intracranial pressure

2.2.8. Diuretics with potassium

- No preparations are included in the Formulary

2.3. ANTI-ARRHYTHMIC DRUGS

2.3.1. Management of arrhythmias

2.3.2. Drugs for arrhythmias

ADENOSINE

- 6mg/2ml injection

Key to abbreviations

- O Licensed preparation being used for an unlicensed indication
- P Preparation is only included in the Paediatric Formulary and is not included in the GGC Adult Formulary
- SP Available as an unlicensed or special preparation

AMIODARONE HYDROCHLORIDE

150mg/3ml injection

FLECAINIDE ACETATE

100mg tablets

150mg/15ml injection

25mg/5ml liquid^{SP}**2.4. BETA-ADRENOCEPTOR BLOCKING DRUGS****ATENOLOL**

25mg, 50mg, 100mg tablets

25mg/5ml syrup

CARVEDILOL

3.125mg tablets

ESMOLOL

100mg/10ml injection

LABETALOL

100mg/20ml injection

PROPRANOLOL

10mg, 40mg tablets

5mg/5ml syrup

1mg/1ml injection

NADALOL^P

80mg tablets

30mg/5ml solution^{SP}**2.5. HYPERTENSION****2.5.1. Vasodilator antihypertensive drugs and pulmonary hypertension****2.5.1.1. Vasodilator antihypertensives****DIAZOXIDE**

50mg tablets

100mg/5ml suspension^{SP}

300mg/20ml injection

MINOXIDIL

2.5mg tablets

SODIUM NITROPRUSSIDE50mg/5ml injection^{SP}**2.5.1.2. Pulmonary hypertension****BOSENTAN**

62.5mg, 125mg tablets

Restricted to initiation and prescribing by specialists in the Scottish Pulmonary Vascular Unit or similar specialists (e.g. on advice from Great Ormond Street Hospital).

EPOPROSTENOL

500microgram infusion

SILDENAFIL25mg tablets^O

10mg/ml powder for oral solution*

2mg/ml suspension^{SP}0.8mg/ml injection^O

Restricted to specialist use only.

Sildenafil injection is further restricted to specialist use in patients with clinically and echo-confirmed pulmonary arterial hypertension that can not be managed by inhaled nitric oxide (iNO) or cannot be weaned from iNO or ECMO, and when oral formulations of sildenafil are not tolerated or inappropriate.

*Please note, this new licensed preparation is a different strength to the unlicensed suspension which has been used previously.

2.5.2. Centrally acting antihypertensive drugs**CLONIDINE**100micrograms/5ml suspension^{SP}

150microgram/ml injection

25microgram, 100microgram tablets

Used for several other unlicensed indications, such as ADHD, tics and Gilles de Tourette syndrome

Key to abbreviations

O Licensed preparation being used for an unlicensed indication

P Preparation is only included in the Paediatric Formulary and is not included in the GGC Adult Formulary

SP Available as an unlicensed or special preparation

2.5.3. Adrenergic neurone blocking drugs
No preparations are included in the Formulary

2.5.4. Alpha-adrenoceptor blocking drugs
DOXAZOSIN
1mg, 2mg tablets
PHENOXYBENZAMINE HYDROCHLORIDE
10mg capsules
100mg/2ml injection
PHEHTOLAMINE MESILATE
10mg/1ml injection

2.5.5. Drugs affecting the renin-angiotensin system

2.5.5.1. Angiotensin-converting enzyme inhibitors

CAPTOPRIL
12.5mg, 25mg tablets
5mg/ml suspension^{SP}
ENALAPRIL MALEATE
2.5mg, 5mg tablets
LISINOPRIL
2.5mg tablets

2.5.5.2. Angiotensin-II receptor antagonists

LOSARTAN
25mg tablets
2.5mg/ml suspension

2.6. NITRATES, CALCIUM-CHANNEL BLOCKERS, AND OTHER ANTIANGINAL DRUGS

2.6.1. Nitrates

GLYCERYL TRINITRATE
50mg/50ml injection

2.6.2. Calcium-channel blockers

AMLODIPINE
5mg tablets
5mg/5ml solution^{SP}
NIFEDIPINE
5mg, 10mg capsules
20mg/ml drops^{SP}
10mg, 20mg modified-release tablets
Modified-release preparations should be prescribing by brand name

2.6.3. Other antianginal drugs
No preparations are included in the Formulary

2.6.4. Peripheral vasodilators and related drugs
No preparations are included in the Formulary

2.7. SYMPATHOMIMETICS

2.7.1. Inotropic sympathomimetics

DOBUTAMINE
250mg/20ml injection
DOPAMINE
200mg/5ml injection
ISOPRENALINE
1mg/ml injection^{SP}

2.7.2. Vasoconstrictor sympathomimetics

EPHEDRINE
30mg/ml injection

Key to abbreviations

O	Licensed preparation being used for an unlicensed indication
P	Preparation is only included in the Paediatric Formulary and is not included in the GGC Adult Formulary
SP	Available as an unlicensed or special preparation

NORADRENALINE (NOREPINEPHRINE)

2mg/ml acid tartrate injection (equivalent to 1mg/ml base)

PHENYLEPHRINE HYDROCHLORIDE

10mg/ml injection

2.7.3. Cardiopulmonary resuscitation

ADRENALINE (EPINEPHRINE)

1 in 10,000 pre-filled syringe (10ml)

1 in 1000 injection (1ml)

2.8. **ANTICOAGULANTS AND PROTAMINE**

2.8.1. Parenteral anticoagulants

ENOXAPARIN

20mg, 40mg, 60mg, 80mg, 100mg pre-filled syringe

300mg/3ml multidose vial

HEPARINISED SALINE

50units/5ml, 200units/2ml

500unit/500ml infusion^{SP}**HEPARIN SODIUM**

1000units/ml (5ml) injection

HEPARIN (PRESERVATIVE FREE)

1000units/ml (5ml) injection

2.8.2. Oral anticoagulants

WARFARIN

500microgram, 1mg, 3mg, 5mg tablets

2.8.3. Protamine sulphate

PROTAMINE SULPHATE

50mg/5ml injection

2.9. **ANTIPLATELET DRUGS****ASPIRIN**

75mg dispersible tablets

CLOPIDOGREL

75mg tablets

2.10. **MYOCARDIAL INFARCTION AND FIBRINOLYSIS**

2.10.1. Management of myocardial infarction

No preparations are included in the Formulary

2.10.2. Fibrinolytic drugs

ALTEPLASE

10mg, 20mg injection

UROKINASE

25,000unit injection

2.11. **ANTIFIBRINOLYTIC DRUGS AND HAEMOSTATICS****APROTININ^{SP}**

10,000units/ml (50ml) injection.

Unlicensed preparation restricted to use in cardiac surgery only

TRANEXAMIC ACID

500mg tablets

500mg/5ml injection

-
- 2.12. **LIPID-REGULATING DRUGS**
COLESTYRAMINE (CHOLESTYRAMINE)
4g sachet
ATORVASTATIN
10mg, 20mg tablet.
SIMVASTATIN^O
10mg, 20mg, 40mg tablet.

-
- 2.13. **LOCAL SCLEROSANTS**
SODIUM TETRADECYL SULPHATE
3% injection (2ml)

-
- 2.14. **DRUGS AFFECTING THE DUCTUS ARTERIOSUS**
IBUPROFEN
5mg/ml (2ml) injection
Maintenance of patency
DINOPROSTONE
1mg/ml injection (0.75ml)

3. RESPIRATORY SYSTEM

3.1. BRONCHODILATORS

3.1.1. Adrenoceptor agonists

SALBUTAMOL

- 100microgram/puff metered dose inhaler (MDI)
- 200microgram/puff dry powder inhaler (Accuhaler®)
- 2.5mg, 5mg nebulules
- 2mg/5ml syrup

SALMETEROL

- 25microgram/puff metered dose inhaler (MDI)
- 50microgram/puff dry powder inhaler (Accuhaler®)

TERBUTALINE

- 500microgram/puff dry powder inhaler (Turbohaler®)

3.1.2. Antimuscarinic bronchodilators

IPRATROPIUM BROMIDE

- 20microgram/puff metered dose inhaler (MDI)
- 250microgram/ml (2ml) nebuliser solution

TIOTROPIUM (SPIRIVA® RESPIMAT®)

- 2.5microgram solution for inhalation
- Restricted to use as an add-on maintenance bronchodilator in children aged 6 years and older with severe asthma who have experienced one or more severe asthma exacerbations in the preceding year.

3.1.3. Theophylline

AMINOPHYLLINE

- 250mg/10ml injection

THEOPHYLLINE

- 60mg, 125mg Slow-release capsules (Slo-phyllin®)

3.1.4. Compound bronchodilator preparations

- No preparations are included in the Formulary

3.1.5. Peak flow meters, inhaler devices, and nebulisers

PEAK FLOW METERS

- Mini-Wright® (standard/low) range

AEROCHAMBER®

- Infant device with mask (orange)
- Child device with mask (yellow)

NEBUHALER®

VOLUMATIC®

3.2. CORTICOSTEROIDS

BECLOMETASONE DIPROPIONATE

- 50microgram/puff, 100microgram/puff metered dose inhaler (MDI)
- Different brands of beclometasone CFC-free inhalers are not equipotent and should be prescribed by brand name for safety reasons. The preferred brand is Clenil Modulite®

BUDESONIDE

- 50microgram/puff, 200microgram/puff metered dose inhaler (MDI)
- 100, 200microgram/puff dry powder inhaler (Turbohaler®)
- 100mcg, 200mcg, 400mcg dry powder inhaler (Easyhaler®)
- 500microgram/2ml, 1mg/2ml nebuliser solution (Respules®)
- Budesonide nebuliser solution is restricted only to hospital inpatient treatment of croup

BUDESONIDE AND FORMOTEROL (SYMBICORT®)

- 100/6, 200/6, 400/12 dry powder inhaler (Turbohaler®)
- 100/6, 200/6 inhalation powder (Symbicort® SMART®)

FLUTICASONE PROPIONATE

- 50microgram/puff, 125microgram/puff, 250microgram/puff metered dose inhaler (MDI)
- 50microgram/puff dry powder inhaler (Accuhaler®)

FLUTICASONE AND SALMETEROL (SERETIDE®)

- 50microgram/puff, 125microgram/puff, 250microgram/puff metered dose inhaler (MDI)
- 100microgram/puff, 250microgram/puff, 500microgram/puff dry powder inhaler (Accuhaler®)

Key to abbreviations

- O Licensed preparation being used for an unlicensed indication
- P Preparation is only included in the Paediatric Formulary and is not included in the GGC Adult Formulary
- SP Available as an unlicensed or special preparation

3.3. CROMOGLICATE AND RELATED THERAPY AND LEUKOTRIENE RECEPTOR ANTAGONISTS

3.3.1. Cromoglicate and related therapy
No preparations are included in the Formulary

3.3.2. Leukotriene receptor antagonists

MONTELUKAST

10mg tablets
4mg sachets
4mg, 5mg chewable tablets
Use for seasonal allergic rhinitis is non-Formulary

3.4. ANTIHISTAMINES, IMMUNOTHERAPY, AND ALLERGIC EMERGENCIES

3.4.1. Antihistamines

Non-sedating antihistamines

CETIRIZINE

10mg tablets
5mg/5ml oral solution

LORATADINE

10mg tablets

Sedating antihistamines

CHLORPHENAMINE (CHLORPHENIRAMINE)

4mg tablets
2mg/5ml syrup
10mg/ml injection

HYDROXYZINE HYDROCHLORIDE

10mg tablets
10mg/5ml syrup

PROMETHAZINE HYDROCHLORIDE

5mg/5ml syrup
25mg/1ml, 50mg/2ml injection

3.4.2. Allergen immunotherapy

MEPOLIZUMAB

Restricted to specialist use as add-on treatment for severe refractory eosinophilic asthma in adolescents and children aged 6 years and older in patients who have eosinophils of at least 150 cells per microlitre ($0.15 \times 10^9/L$) at initiation of treatment and have had at least four asthma exacerbations in the preceding year or are receiving maintenance treatment with oral corticosteroids.

3.4.3. Allergic emergencies

ADRENALINE (EPINEPHRINE)

1 in 10,000 injection
150microgram, 300microgram auto injector (e.g. Epipen®, Anapen®, Jext®)

ICATIBANT ACETATE

30mg pre-filled syringe
Symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adolescents and children ≥ 2 years with C1-esterase-inhibitor deficiency is restricted to specialist use only.

3.5. RESPIRATORY STIMULANTS AND PULMONARY SURFACTANTS

3.5.1. Respiratory stimulants

CAFFEINE CITRATE

10mg/ml injection
10mg/ml oral solution^{SP}
20mg/ml infusion
20mg/ml oral solution
Restricted to specialist use.

DOXAPRAM

100mg/5ml injection

Key to abbreviations

O	Licensed preparation being used for an unlicensed indication
P	Preparation is only included in the Paediatric Formulary and is not included in the GGC Adult Formulary
SP	Available as an unlicensed or special preparation

3.5.2. Pulmonary surfactants

PORACTANT ALFA (CUROSURF®)

120mg/1.5ml and 240mg/3ml suspension for administration by endotracheal tube.

Restricted to specialist use in neonatal respiratory distress by consultant paediatricians and specialist registrars.

3.6. OXYGEN

OXYGEN

Acute oxygen therapy must be prescribed on drug Kardex indicating flow and concentration

Assessment and prescribing of long-term home oxygen therapy is restricted to respiratory physicians. National systems are in place to order oxygen equipment. Please contact respiratory team or pharmacy for further information.

WATER FOR INHALATION

500ml

3.7. MUCOLYTICS

DORNASE ALFA (PULMOZYME®)

2500unit/2.5ml nebuliser solution.

Specialist initiation only.

3.8. AROMATIC INHALATIONS

MENTHOL CRYSTALS

3.9. COUGH PREPARATIONS

3.9.1. Cough suppressants

Cough may be a symptom of underlying disease which should be addressed before prescribing cough suppressants. See MHRA/CHM advice March 2008 and February 2009 on use of over the counter cough and cold remedies. See MHRA/CHM advice October 2010 on use of codeine-containing preparations.

3.9.2. Expectorant and demulcent cough preparations

SIMPLE LINCTUS (CITRIC ACID)**SIMPLE LINCTUS PAEDIATRIC (CITRIC ACID)**

3.10. SYSTEMIC NASAL DECONGESTANTS

PSEUDOEPHEDRINE

30mg/5ml elixir

Restricted to patients 6 years of age and older

4. CENTRAL NERVOUS SYSTEM

4.1. HYPNOTICS AND ANXIOLYTICS

MELATONIN

Generic 3mg immediate release capsules are available, are listed in the Scottish Drug Tariff part 7U (unlicensed), and are the preferred melatonin preparation.

Melatonin is available as a licensed modified release tablet (Circadin®). Oral solution is unlicensed in the UK but manufactured as a 'special' by various manufacturers.

The Slenyto® 1mg and 5mg prolonged release tablets are not recommended by SMC and remain non-formulary.

4.1.1. Hypnotics

PROMETHAZINE HYDROCHLORIDE

5mg/5ml syrup (also see section 3.4.1)

CHLORAL HYDRATE

500mg/5ml oral solution^{SP}

4.1.2. Anxiolytics

DIAZEPAM

2mg, 5mg tablets

2mg/5ml suspension

2.5mg, 5mg, 10mg rectal tubes

(Also see section 4.8.2, 10.2.2 and 15.1.4)

4.1.3. Barbiturates

No preparations are included in the Formulary

4.2. DRUGS USED IN PSYCHOSES AND RELATED DISORDERS

The prescription of antipsychotic medicines in children should only be done under the direction of a consultant psychiatrist experienced in treating children.

4.2.1. Antipsychotic drugs

ARIPIRAZOLE

5mg, 10mg tablets

10mg orodispersible tablets

1mg/ml oral solution

Treatment for up to 12 weeks of moderate to severe manic episodes in Bipolar Disorder I in adolescents aged 13 years and older is restricted to specialist initiation and management under the supervision of a child/ adolescent psychiatrist.

CHLORPROMAZINE HYDROCHLORIDE

25mg tablets

25mg/5ml oral solution

50mg/2ml injection

LEVOMEPRIMAZINE (METHOTRIMEPRAZINE)

25mg/ml injection

Not used for psychoses but used for palliative care and other indications

OLANZAPINE

2.5mg, 5mg, 10mg tablets

5mg, 10mg orodispersible tablets

PROMETHAZINE

10mg tablets and 5mg/5ml suspension

RISPERIDONE

1mg, 3mg tablets and 1mg/ml liquid

QUETIAPINE

25mg, 100mg, 200mg tablets

THIORIDAZINE

25mg/5ml syrup

4.2.2. Antipsychotic depot injections

No preparations are included in the Formulary

4.2.3. Antimanic drugs

No preparations are included in the Formulary

Key to abbreviations

O	Licensed preparation being used for an unlicensed indication
P	Preparation is only included in the Paediatric Formulary and is not included in the GGC Adult Formulary
SP	Available as an unlicensed or special preparation

4.3. ANTIDEPRESSANT DRUGS**4.3.1. Tricyclic antidepressant drugs**

No preparations are included in the Formulary

4.3.2. Monoamine-oxidase inhibitors

No preparations are included in the Formulary

4.3.3. Selective serotonin re-uptake inhibitors

These preparations should only be initiated after full consideration of the risks versus the benefits. Current best evidence indicates that fluoxetine may be the preferred first choice as it is licensed in children aged 8 years and above with moderate to severe major depressive episodes (see product literature for full information).

FLUOXETINE

20mg capsules

CITALOPRAM

20mg tablets

SERTRALINE

50mg, 100mg tablets

4.3.4. other antidepressant drugs

No preparations are included in the Formulary

4.4. CNS STIMULANTS AND OTHER DRUGS FOR ATTENTION DEFICIT HYPERACTIVITY DISORDER**ATOMOXETINE**

10mg, 18mg, 25mg, 40mg capsules and 4mg/ml oral solution

Restricted to use in children over 6 years and adolescents who do not respond to stimulants or in whom stimulants are contraindicated or not tolerated. The oral solution is restricted to patients who are unable to swallow capsules.

DEXAMFETAMINE

5mg tablets

GUANFACINE

1mg, 2mg, 3mg, 4mg prolonged release tablets

Restricted to specialist initiation for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents 6 to 17 years old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective. Treatment must be used as part of a comprehensive ADHD treatment programme, typically including psychological, educational and social measures.

LISDEXAMFETAMINE

20mg, 30mg, 40mg, 50mg, 60mg 70mg capsules

Restricted to specialist initiation for children aged 6 years of age and over as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder (ADHD).

METHYLPHENIDATE

5mg, 10mg tablets

Modified-release tablets (see BNF for Children and restrictions below)

Restricted to initiation by child or adolescent psychiatrists or paediatricians with expertise in ADHD.

Modified-release preparations are restricted to second-line therapy where there is evidence of compliance problems or where clear evidence that administration of a midday dose is problematic or inappropriate

Modified-release preparations should be prescribed by brand name. Xaggitin XL[®] is the preferred brand of sustained-release methylphenidate.

4.5. DRUGS USED IN THE TREATMENT OF OBESITY

No preparations are included in the Formulary

4.6. DRUGS USED IN NAUSEA AND VERTIGO**APREPITANT**

80mg, 125mg hard capsules

125mg powder for oral suspension

Restricted to specialist use only in accordance with local protocol.

CYCLIZINE

50mg tablets

50mg/ml injection

Key to abbreviations

O	Licensed preparation being used for an unlicensed indication
P	Preparation is only included in the Paediatric Formulary and is not included in the GGC Adult Formulary
SP	Available as an unlicensed or special preparation

DOMPERIDONE

10mg tablets
5mg/5ml suspension

FOSAPREITANT (IVEMEND®)

150mg infusion
Restricted to specialist use only in accordance with local/national protocol

HYOSCINE HYDROBROMIDE

300microgram tablets
1mg/72hours patch

LEVOMEPRMAZINE

6mg^{SP}, 25mg tablets
25mg/ml injection

LORAZEPAM

4mg/ml injection

METOCLOPRAMIDE

10mg tablets
5mg/5ml syrup
10mg/2ml injection

ONDANSETRON

4mg tablets
4mg/5ml SF syrup
4mg/2ml, 8mg/4ml injection
4mg, 8mg orodispersible films (Setofilm®), which are restricted to patients with an enhanced risk of aspiration or who experience difficulties in swallowing.

PALONOSETRON

250 microgram injection.
Restricted to specialist use for the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy and prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy, in paediatric patients 1 month of age and older.

4.7. ANALGESICS**4.7.1. Non-opioid analgesics**

For non-steroidal anti-inflammatory medicines, see section 10.1.1

PARACETAMOL

500mg tablets
500mg soluble tablets
120mg/5ml sugar-free suspension,
250mg/5ml sugar-free suspension (not commonly used in hospitals)
60mg, 120mg, 240mg, 500mg suppositories
10mg/ml infusion (restricted to hospital use only in accordance with local protocol)

4.7.2. Opioid analgesics**DIAMORPHINE**

5mg, 10mg, 30mg, 100mg, 500mg injection

DIHYDROCODEINE

30mg tablets
10mg/5ml elixir

FENTANYL

100microgram/2ml
500microgram/10ml injection
12microgram/hour, 25microgram/hour, 50microgram/hour, 75microgram/hour and 100microgram/hour patch

METHADONE

10mg/ml injection^{SP}
Restricted to initiation by the Pain Team

MORPHINE SULPHATE

10mg, 20mg tablets (Sevredol®)
10mg, 30mg, 60mg, 100mg SR tablets (MST®)
10mg/5ml, 100microgram/ml^{SP}, 200microgram/ml^{SP} oral solution
20mg, 30mg, 60mg, 100mg suspension (MST® Continus)
10mg/1ml, 60mg/2ml injection, 100mg/50ml injection

Key to abbreviations

O	Licensed preparation being used for an unlicensed indication
P	Preparation is only included in the Paediatric Formulary and is not included in the GGC Adult Formulary
SP	Available as an unlicensed or special preparation

- 4.7.3. Neuropathic pain
AMITRIPTYLINE^O
 10mg, 25mg tablets
 25mg/5ml oral solution
 Restricted to initiation on the advice of the Pain Team or on the advice of neurology.

CARBAMAZEPINE

See section 4.8.1
 Restricted to initiation on the advice of the Pain Team

GABAPENTIN

See section 4.8.1
 Restricted to initiation on the advice of the Pain Team

- 4.7.4. Antimigraine drugs

PIZOTIFEN

500microgram tablets
 250microgram/5ml elixir

SUMATRIPTAN

50mg tablets

4.8. ANTIEPILEPTICS**4.8.1. Control of epilepsy**

Where it is essential in all cases to maintain a patient on a specific brand or manufacturer's preparation, this is indicated in the relevant Formulary entry. For all other antiepileptic medicines, when being used to treat epilepsy, there is no requirement to be maintained on a specific brand or manufacturer's preparation, unless the prescriber considers, following a discussion with each individual patient at the next review, that an individual patient's circumstances require the need for continuity of supply of a particular specific manufacturer or brand (e.g. seizure risk, treatment history or other concerns, such as patient anxiety, risk of confusion or dosing errors).

ACETAZOLAMIDE

250mg tablets. See section 2.2.7 and 11.6 for other uses

BRIVARACETAM (BRIVIACT[®])

Restricted to specialist initiation for adjunctive therapy in children from age 4 years with refractory epilepsy for the treatment of partial-onset seizures with or without secondary generalisation..

CARBAMAZEPINE

Note: Patients should be maintained on a specific brand or manufacturer's preparation and prescribing by brand name should be followed where possible.

100mg tablets
 200mg MR tablets
 100mg/5ml suspension
 125mg, 250mg suppositories

CLOBAZAM

10mg tablets

CLONAZEPAM

500microgram, 2mg tablets

ESLICARBAZEPINE

Use as adjunctive therapy in adolescents and children age 6 years and over with partial-onset seizures with or without secondary generalisation is restricted to specialist initiation in patients with highly refractory epilepsy who have been heavily pre-treated and remain uncontrolled with existing anti-epileptic drugs.

ETHOSUXIMIDE

25mg capsules
 250mg/5ml syrup

EVEROLIMUS

2mg, 3mg, 5mg dispersible tablets are accepted for use as adjunctive treatment of patients aged ≥ 2 years whose refractory partial-onset seizures, with or without secondary generalisation, are associated with tuberous sclerosis complex (TSC). Its use is restricted to specialist use only.

GABAPENTIN

100mg, 300mg capsules

LACOSAMIDE

50mg, 100mg tablets
 Restricted to adjunctive use in patients with refractory epilepsy.

Use as monotherapy for partial-onset seizures with or without secondary generalisation in adolescents and children from 4 years of age is not recommended by SMC and remains non-Formulary.

Key to abbreviations

- O Licensed preparation being used for an unlicensed indication
 P Preparation is only included in the Paediatric Formulary and is not included in the GGC Adult Formulary
 SP Available as an unlicensed or special preparation

LAMOTRIGINE

25mg, 50mg, 100mg tablets
5mg, 25mg dispersible tablets

LEVETIRACETAM

250mg tablets
100mg/ml oral solution
100mg/ml intravenous infusion (hospital use only)

NITRAZEPAM

2.5mg/5ml suspension

OXCARBAZEPINE

150mg tablets
300mg/5ml suspension^P

PERAMPANEL

2mg, 4mg, 6mg, 8mg, 10mg, 12mg tablets

Use as adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in patients with epilepsy aged 12 years and older is restricted to initiation by specialists in epilepsy

PHENOBARBITONE

Note: Patients should be maintained on a specific brand or manufacturer's preparation and prescribing by brand name should be followed where possible

15mg, 30mg, 60mg tablets
50mg/5ml oral solution^{SP} (alcohol and sugar-free)
15mg/ml, 30mg/ml, 60mg/ml injection

PHENYTOIN

Note: Patients should be maintained on a specific brand or manufacturer's preparation and prescribing by brand name should be followed where possible

25mg, 50mg, 100mg capsules (Epanutin®)
50mg chewable tablets
30mg/5ml suspension
250mg/5ml injection

PRIDOXAL-5-PHOSPHATE^{SP}

50mg tablets

RUFINAMIDE

100mg, 200mg, 400mg tablets
40mg/ml oral suspension

Rufinamide is restricted to use in patients who have failed treatment with or are intolerant of alternative traditional antiepileptic drugs.

Use as adjunctive therapy in the treatment of seizures associated with Lennox-Gastaut syndrome in patients 1 years to ≤4 years is restricted to specialist initiation in patients who have failed treatment with or are intolerant of other antiepileptic drugs.

SODIUM VALPROATE

200mg, 500mg EC tablets
100mg crushable tablets
200mg, 500mg MR tablets (Epilim® Chrono)
200mg/5ml sugar-free liquid
50mg MR granules (Epilim® Chronosphere)
400mg injection

STIRIPENTOL

250mg, 500mg hard capsule
250mg, 500mg powder for oral suspension in sachet
Restricted to specialist initiation

TOPIRAMATE

25mg tablets
15mg, 25mg sprinkle capsules

TRIPLE BROMIDE^{SP}

1200mg/5ml solution

VIGABATRIN

500mg tablets
500mg sachets

ZONISAMIDE

25mg, 50mg, 100mg capsules

Restricted to initiation on the advice of specialists (paediatric neurologists or paediatricians with an expertise in epilepsy).

Key to abbreviations

O	Licensed preparation being used for an unlicensed indication
P	Preparation is only included in the Paediatric Formulary and is not included in the GGC Adult Formulary
SP	Available as an unlicensed or special preparation

4.8.2. Drugs used in status epilepticus

CLONAZEPAM

1mg/1ml injection

DIAZEPAM

2.5mg, 5mg, 10mg rectal tubes

10mg/2ml injection (emulsion)

LORAZEPAM

4mg/1ml injection (other strengths may be in use)

MIDAZOLAM

5mg/ml oromucosal solution available in 2.5mg, 5mg, 7.5mg and 10mg pre-filled oral syringe.

10mg/1ml oromucosal solution pre-filled syringe

PARALDEHYDE50% rectal solution in olive oil^{SP}**PHENYTOIN**

250mg/5ml injection

4.8.3. Febrile convulsions

See BNF for Children

4.9. DRUGS USED IN DYSTONIAS AND RELATED DISORDERS

4.9.1. Dopaminergic drugs used in dystonias

CO-CARELDOPA^O

12.5/50 tablets

4.9.2. Antimuscarinic drugs used in dystonias

PROCYCLIDINE

5mg tablets

10mg/2ml injection

4.9.3. drugs used in essential tremor, chorea, tics, and related disorders

BOTULINUM TOXIN A

50unit, 500unit injection

Prescribe by brand name, as indications and bioequivalence may vary between preparations

4.10. DRUGS USED IN SUBSTANCE DEPENDENCE

No preparations are included in the Formulary

4.11. DRUGS FOR DEMENTIA

No preparations are included in the Formulary

5. INFECTIONS

5.1. ANTIBACTERIAL DRUGS

5.1.1. Penicillins

AMOXICILLIN

250mg, 500mg capsules
125mg/5ml, 250mg/5ml oral SF suspension
250mg, 500mg injection
3g sachets

CO-AMOXICLAV

125/31 and 250/62 suspension
375mg tablets
600mg and 1200mg injection

BENZYLPENICILLIN

600mg injection

FLUCLOXACILLIN

250mg, 500mg capsules
125mg/5ml and 250mg/5ml SF suspension
250mg, 500mg, 1g injection

PHENOXYMETHYLPENICILLIN (PENICILLIN V)

250mg tablets
125mg/5ml, 250mg/ml suspension

PIPERACILLIN WITH TAZOBACTAM

2.25g, 4.5g injection

5.1.2. Cephalosporins and other beta-lactams

CEFOTAXIME

500mg, 1g injection

CEFTAZIDIME

250mg, 500mg, 1g, 2g injection

CEFUROXIME

250mg, 750mg, 1500mg injection

CEFALEXIN

250mg tablets
250mg/5ml suspension

CEFTRIAXONE

250mg, 1g injection

AZTREONAM

500mg, 1g, 2g injection

Restricted to use for Cystic Fibrosis patients or on the advice of microbiology or infectious disease physicians

MEROPENEM

500mg, 1g injection

IMIPENEM WITH CILASTIN (PRIMAXIN®)

500mg injection

5.1.3. Tetracyclines

See section 13.6.2 for tetracyclines used in the treatment of acne

DOXYCYCLINE

100mg/5ml Injection^{SP}

5.1.4. Aminoglycosides

AMIKACIN

100mg/2ml, 500mg/2ml injection

GENTAMICIN

20mg/2ml, 80mg/2ml injection
5mg/5ml intrathecal injection

TOBRAMYCIN

40mg/1ml, 80mg/2ml injection
60mg/ml, 75mg/ml nebuliser solution

Restricted to use for Cystic Fibrosis patients or on the advice of microbiology or infectious disease physicians.

Key to abbreviations

O	Licensed preparation being used for an unlicensed indication
P	Preparation is only included in the Paediatric Formulary and is not included in the GGC Adult Formulary
SP	Available as an unlicensed or special preparation

5.1.5. Macrolides

AZITHROMYCIN

250mg capsules
200mg/5ml suspension

CLARITHROMYCIN

250mg tablets
125mg/5ml paediatric suspension
500mg injection

ERYTHROMYCIN

250mg tablets
125mg/5ml, 250mg/5ml suspension
1g injection

5.1.6. Clindamycin

CLINDAMYCIN

75mg capsules
75mg/5ml suspension^{SP}
300mg/2ml injection

5.1.7. Some other antibacterials

COLOMYCIN^O

1 mega unit, 2 mega unit injection used for nebulisation

LINEZOLID

2mg/ml IV infusion (300ml)
Restricted to use only on the advice of microbiology or infectious disease physicians.

SODIUM FUSIDATE

250mg tablets
175mg/5ml suspension,
500mg injection

TEICOPLANIN

200mg injection

VANCOMYCIN

500mg injection

5.1.8. Sulphonamides and trimethoprim

CO-TRIMOXAZOLE

480mg tablets
240mg/5ml paediatric suspension
480mg/5ml suspension
480mg/5ml IV infusion

TRIMETHOPRIM

100mg tablets
50mg/5ml SF suspension

5.1.9. Antituberculosis drugs

ETHAMBUTOL

100mg tablets

ISONIAZID

50mg, 100mg tablets
50mg/5ml liquid^{SP}

PYRAZINAMIDE

500mg tablets^{SP}

RIFAMPACIN

150mg, 300mg capsules
100mg/5ml suspension

RIFINAH[®]

Available as '150' and '300' preparations

5.1.10. Antileprotic drugs

DAPSONE

Restricted to specialist initiation

Key to abbreviations

- O Licensed preparation being used for an unlicensed indication
P Preparation is only included in the Paediatric Formulary and is not included in the GGC Adult Formulary
SP Available as an unlicensed or special preparation

- 5.1.11. Metronidazole
METRONIDAZOLE
 200mg tablets
 200mg/5ml suspension
 500mg/100ml IV infusion
 500mg suppositories
- 5.1.12. Quinolones
CIPROFLOXACIN
 250mg tablets
 250mg/5ml suspension
 100mg/50ml, 200mg/100ml IV infusion
- 5.1.13. Urinary-tract infections
TRIMETHOPRIM
 100mg tablets
 50mg/5ml SF suspension
NITROFURANTOIN
 50mg capsules
 25mg/5ml suspension

5.2. **ANTIFUNGAL DRUGS**

AMPHOTERICIN

- 50mg infusion
 50mg liposomal infusion

CASPOFUNGIN

- 50mg, 70mg IV infusion
 Restricted to hospital use only.

Caspofungin is restricted to paediatric patients with fluconazole-resistant *Candida* infection unresponsive to or who cannot tolerate amphotericin B therapy. It is not recommended by SMC for invasive aspergillosis. Restricted for empirical therapy for presumed fungal infections in febrile, neutropenic paediatric patients on the advice of microbiologists or specialists in infectious diseases.

FLUCONAZOLE

- 50mg, 200mg capsules
 50mg/5ml suspension
 50mg/25ml, 200mg/10ml injection

ITRACONAZOLE

- 100mg capsules
 50mg/5ml SF oral liquid

MICONAZOLE

- 25mg/ml oral gel

NYSTATIN

- 100,000 units/ml suspension

POSACONAZOLE

- 200mg/5ml suspension
 Restricted to hospital use only.

Use for the prophylaxis of invasive fungal infections in immunocompromised patients is restricted to patients in whom there is a specific risk of aspergillus infection or where fluconazole or itraconazole are not tolerated in accordance with local protocol.

VORICONAZOLE

- 50mg, 200mg tablets
 200mg/5ml oral suspension
 200mg IV infusion

Restricted to hospital use only.

Restricted to use in secondary care on the advice of microbiologist/ haematologist primarily in immuno-compromised patients with progressive, possibly life-threatening infections. Treatment of candidaemia in non-neutropenic patients is restricted to those who cannot tolerate amphotericin B therapy or who are at an increased risk of serious side effects with amphotericin.

5.3. ANTIVIRAL DRUGS**5.3.1. HIV infection**

See BNF for Children and GGC Adult Formulary for restrictions on use. All antivirals are to be used under the supervision of a Paediatric HIV specialist.

5.3.2. Herpes virus infections**ACICLOVIR**

200, 400mg dispersible tablets
200mg/5ml suspension
250mg/10ml for IV infusion

CIDOFOVIR

375mg/5ml injection (specialist use only)

GANCICLOVIR

500mg infusion

VALGANCLOVIR

450mg tablets
250mg/5ml oral solution

Restricted to use by HIV specialists, ophthalmologists specialising in ocular issues associated with HIV infection and physicians experienced in the care of post-transplant patients.

5.3.3. Viral hepatitis

Also see BNF for Children and GGC Adult Formulary.

PEGYLATED INTERFERON ALFA-2B (VIRAFERON PEGOL®)

Restricted to specialist use in a combination regimen with ribavirin for the treatment of children 3 years of age and older and adolescents, who have chronic hepatitis C, not previously treated, without liver decompensation, and who are positive for HCV-RNA

PEGYLATED INTERFERON ALFA-2A (PEGASYS®)

Restricted to prescribing by specialists in paediatric infectious disease or paediatric gastroenterology. Formulary in combination with ribavirin for the treatment of chronic hepatitis C (CHC) in treatment-naïve children and adolescents 5 years of age or older who are positive for serum hepatitis-C-virus ribonucleic acid (HCV-RNA).

ENTECAVIR (BARACLUDE®)

Restricted to use by specialists in paediatric infectious diseases for the treatment of chronic hepatitis B virus infection in nucleoside naïve paediatric patients from 2 to <18 years of age with compensated liver disease who have evidence of active viral replication and persistently elevated serum alanine aminotransferase levels, or histological evidence of moderate to severe inflammation and/or fibrosis.

5.3.4. Influenza**OSELTAMIVIR**

30mg, 45mg, 75mg capsule
6mg/ml SF suspension

Use in the prophylaxis and treatment of influenza is subject to NICE TA158 and TA168

5.3.5. Respiratory syncytial virus**PALIVIZUMAB**

50, 100mg injection (restricted to use according to West of Scotland Treatment Protocol)

RIBAVIRIN

1200mg/12ml injection^{SP} (specialist use only)

5.4. ANTIPROTOZOAL DRUGS**5.4.1. Antimalarials****CHLOROQUINE**

50mg/5ml syrup
200mg/5ml injection

PYRIMETHAMINE^P

25mg tablets

PRIMAQUINE^P

7.5mg tablets

PROGUANIL

100mg tablets

QUININE

600mg/2ml injection

Key to abbreviations

O	Licensed preparation being used for an unlicensed indication
P	Preparation is only included in the Paediatric Formulary and is not included in the GGC Adult Formulary
SP	Available as an unlicensed or special preparation

Quinine IV should be administered with caution under the supervision of a specialist in infectious diseases.

- 5.4.2. Amoebicides
See metronidazole (section 5.1.11)
- 5.4.3. Trichomonacides
See metronidazole (section 5.1.11)
- 5.4.4. Antigiardial drugs
See metronidazole (section 5.1.11)
- 5.4.5. Leishmaniacides
See BNF for Children
- 5.4.6. Trypanocides
See BNF for Children
- 5.4.7. Drugs for toxoplasmosis
PYRIMETHAMINE^P
50mg tablets
Restricted to specialist use in combination with sulfadiazine
- 5.4.8. Drugs for pneumocystis pneumonia
ATOVAQUONE
750mg/5ml suspension
Restricted to use only on the advice of a specialist in infectious diseases
CO-TRIMOXAZOLE
480mg tablets
240mg/5ml paediatric suspension
480mg/5ml adult suspension
480mg/5ml for IV infusion
DAPSONE
See section 5.1.10
PENTAMIDINE
300mg injection

5.5. ANTHELMINTICS

- 5.5.1. Drugs for threadworms
MEBENDAZOLE
100mg tablets
PIPERAZINE
Piperazine 4g/Sennosides 15.3mg sachet (Pripsen®)
- 5.5.2. Ascaricides
See BNF for Children
- 5.5.3. Drugs for tapeworm infections
See BNF for Children
- 5.5.4. Drugs for hookworms
See BNF for Children
- 5.5.5. Schistosomicides
See BNF for Children
- 5.5.6. Filaricides
See BNF for Children
- 5.5.7. drugs for cutaneous larva migrans
See BNF for Children
- 5.5.8. Drugs for strongyloidiasis
See BNF for Children

Key to abbreviations

- O Licensed preparation being used for an unlicensed indication
- P Preparation is only included in the Paediatric Formulary and is not included in the GGC Adult Formulary
- SP Available as an unlicensed or special preparation

6. ENDOCRINE SYSTEM

6.1. DRUGS USED IN DIABETES

6.1.1. Insulins

HUMAN SOLUBLE INSULIN

Actrapid®, Novorapid®

HUMAN ISOPHANE INSULIN

Insulatard®

BISPHASIC INSULIN

Humulin M3®

INSULIN LISPRO (HUMALOG®)

Humalog®

INSULIN DETEMIR (LEVEMIR®)

Restricted to initiation by consultant diabetologists in children aged 1 year and over, and adolescent patients with severe/frequent nocturnal hypoglycaemia in patients unable to achieve good glycaemic control with established insulins. Not for routine use in type 2 diabetes unless patient suffers from recurrent episodes of hypoglycaemia.

INSULIN GLARGINE (LANTUS®)

Restricted to the initiation by consultant diabetologists for the treatment of diabetes mellitus in children aged 2 years and above in patients with type 1 diabetes who are at risk of or experience unacceptable frequency and/or severity of nocturnal hypoglycaemia on attempting to achieve better hypoglycaemic control during treatment with established insulins. It is also acceptable as a once daily insulin therapy for patients who require carer administration of their insulin. In patients with type 2 diabetes it should be restricted to those who suffer from recurrent episodes of hypoglycemia or require assistance with their insulin injections.

6.1.2. Oral antidiabetic drugs

METFORMIN

500mg tablets

500mg in 5ml SF oral solution

Excludes modified-release preparations

6.1.3. Diabetic ketoacidosis

See BNF for Children and DKA protocol on StaffNet for further information on the management of diabetic ketoacidosis.

6.1.4. Treatment of hypoglycaemia

DIAZOXIDE^P

50mg tablets

100mg/5ml suspension^{SP}

300mg/20ml injection

GLUCAGON

1mg injection

GLUCOSE

Glucose 10% IV infusion

Glucose oral gel (Glucogel®)

OCTREOTIDE^O

50, 100 microgram/ml injection

CHLOROTHIAZIDE^O

See section 2.2.1 for details

6.1.5. Treatment of diabetic nephropathy and neuropathy

See BNF for Children

6.1.6. Diagnostic and monitoring agents for diabetes mellitus

See BNF for Children

6.2. THYROID AND ANTITHYROID DRUGS

6.2.1. Thyroid hormones

LEVOTHYROXINE

25microgram, 50microgram, 100microgram tablets

LIOTHYRONINE

20microgram injection

The injection is restricted to specialist use only.

Key to abbreviations

O	Licensed preparation being used for an unlicensed indication
P	Preparation is only included in the Paediatric Formulary and is not included in the GGC Adult Formulary
SP	Available as an unlicensed or special preparation

- 6.2.2. Antithyroid drugs
CARBIMAZOLE
 5mg, 20mg tablets
AQUEOUS IODINE (LUGOL'S IODINE)
 130mg/ml solution
 Restricted to specialist use only.
PROPYLTHIOURACIL
 50mg tablets
 Restricted to specialist initiation.
-
- 6.3. **CORTICOSTEROIDS**
 6.3.1. Replacement therapy
FLUCORTISONE ACETATE
 100microgram tablets
HYDROCORTISONE
 10mg tablets
 Hydrocortisone sodium phosphate 100mg injection (preferred for home use)
 Hydrocortisone sodium succinate 100mg injection
 Hydrocortisone granules (Alkindi®) are restricted to use in children up to age 6 years in whom hydrocortisone must otherwise be given by crushing or splitting tablets or by using specially-prepared solutions or buccal tablets in order to administer an age-appropriate dose.
- 6.3.2. Glucocorticoid therapy
DEXAMETHASONE
 500microgram, 2mg tablets
 10mg/5ml elixir^{SP}
 10mg/2ml injection
METHYLPREDNISOLONE
 40mg, 500mg injection
 40mg/ml depot injection
PREDNISOLONE
 1mg, 5mg, 25mg tablets
 5mg soluble tablets
-
- 6.4. **SEX HORMONES**
 6.4.1. Female sex hormones
ETHINYLESTRADIOL
 10microgram tablets
 2mg tablets^{SP}
NORETHISTERONE
 5mg tablets
- 6.4.2. Male sex hormones and antagonists
TESTOSTERONE
 Testosterone undecanoate 40mg capsules
 Testosterone propionate 100mg, 250mg oily injection
 Testosterone enantate 250mg/ml oily injection
GOSERELIN
 10.8mg implant
 Restricted to specialist initiation for precocious puberty
TRIPTORELIN
 3.75mg, 11.25mg depot injection
 Restricted to specialist initiation for precocious puberty
- 6.4.3. Anabolic steroids
OXANDROLONE^{SP}
 2.5mg tablets

6.5. HYPOTHALAMIC AND PITUITARY HORMONES**6.5.1. Hypothalamic and anterior pituitary hormones including growth hormones****CHORIONIC GONADOTROPHIN**

5000 units injection

GONADORELIN

100microgram injection

PROTERELIN

200microgram/2ml injection

SOMATROPIN (RECOMBINANT HUMAN GROWTH HORMONE)

The treatment of growth disturbance in short children born small for gestational age and who have failed to show catch-up growth by 4 years of age or later is restricted to initiation and monitoring by a paediatrician with expertise in managing childhood growth disorders and growth hormone therapy.

TETRACOSACTIDE (TETRACOSACTRIN)

250microgram/ml injection (Synacthen®)

1mg/1ml depot injection (Synacthen Depot®)

6.5.2. Posterior pituitary hormones and antagonists**ARGIPRESSIN**

20units/ml injection

DESMOPRESSIN

200microgram tablets

120microgram, 240microgram oral lyophilisates

100microgram/ml intranasal solution

4microgram/ml injection

10microgram/dose nasal spray

150microgram/dose nasal spray (only for use in the management of mild haemophilia A or Von Willebrand disease)

6.6. DRUGS AFFECTING BONE METABOLISM**6.6.1. Calcitonin**

See BNF for Children (restricted to specialist use only)

6.6.2. Bisphosphonates**DISODIUM PAMIDRONATE**

15mg IV infusion

6.7. OTHER ENDOCRINE DRUGS**6.7.1. Bromocriptine and other dopaminergic drugs**

No preparations are included in the Formulary

6.7.2. Drugs affecting gonadotrophins

See section 6.4.2

6.7.3. Metyrapone

No preparations are included in the Formulary

6.7.4. Somatomedins**MECASERMIN**

10mg/ml injection

Restricted to specialist use only in accordance with protocol

7. OBSTETRICS, GYNAECOLOGY, AND URINARY-TRACT DISORDERS**7.1. DRUGS USED IN OBSTETRICS**

No preparations are included in the Formulary

7.2. TREATMENT OF VAGINAL AND VULVAL CONDITIONS**7.2.1. Preparations for vaginal and vulval changes**

No preparations are included in the Formulary

7.2.2. Vaginal and vulval infections**CLOTRIMAZOLE**

1% cream

100mg, 500mg pessaries

7.3. CONTRACEPTIVES**7.3.1. Combined hormonal contraceptives**

See GGC Adult Formulary and BNF for Children

7.3.2. Progestogen-only contraceptives

No preparations are included in the Formulary

7.3.3. Spermicidal contraceptives

No preparations are included in the Formulary

7.3.4. Contraceptive devices

No preparations are included in the Formulary

7.3.5. Emergency contraception

No preparations are included in the Formulary

7.4. DRUGS FOR GENITO-URINARY DISORDERS**7.4.1. Drugs for urinary retention****DOXAZOSIN**

1mg, 2mg tablets

7.4.2. Drugs for urinary frequency, enuresis, and incontinence**OXYBUTYNIN**

5mg tablets

5mg, 10mg modified-release tablets

7.4.3. Drugs used in urological pain**POTASSIUM CITRATE**

Effercitrate® tablets

SODIUM BICARBONATE

600mg tablets

8.4% (1mmol/ml) oral solution^{SP}

7.4.4. Bladder instillations and urological surgery**CHLORHEXADINE 0.02%**

100ml Uro-Tainer®

SODIUM CHLORIDE 0.9%

100ml Uro-Tainer®

7.4.5. Drugs for erectile dysfunction

No preparations are included in the Formulary

Key to abbreviations

- O Licensed preparation being used for an unlicensed indication
 P Preparation is only included in the Paediatric Formulary and is not included in the GGC Adult Formulary
 SP Available as an unlicensed or special preparation

8. MALIGNANT DISEASE AND IMMUNOSUPPRESSION**8.1. CYTOTOXIC DRUGS**

Cytotoxic medicines should only be used by or under the direction of an experienced clinician and treatment should follow recognised approved protocols

Drugs for cytotoxic-induced side effects

ALLOPURINOL

100mg tablets

100mg/5ml suspension^{SP}

FOLINIC ACID

15mg tablets

50mg/5ml injection

MESNA

400mg/4ml, 1000mg/10ml injection

RASBURICASE

1.5g, 7.5mg injection

GELCLAIR[®]

15ml sachets

8.1.1. Alkylating drugs**BUSULFAN (BUSULPHAN)**

2mg tablets

6mg/ml IV infusion

CHLORAMBUCIL

2mg tablets

CYCLOPHOSPHAMIDE

500mg, 1g injection

50mg tablets

Suspension^{SP}

IFOSFAMIDE

500mg, 1g, 2g injection

MELPHALEN

100mg injection

8.1.2. Cytotoxic antibiotics**BLEOMYCIN**

15mg injection

DACTINOMYCIN (ACTINOMYCIN D)

500microgram injection

DAUNORUBICIN

20mg injection

DOXORUBICIN

10mg, 50mg injection

EPIRUBICIN

10mg, 50mg injection

MITOMYCIN

2mg injection

MITOXANTRONE (MITOZANTRONE)

2mg/ml IV infusion (available as 10ml, 12.5ml and 15ml vials)

8.1.3. Antimetabolites**CLOFARABINE**

1mg/ml (20ml) injection

CYTARABINE

20mg/ml (5ml) and 100mg/ml (10ml) injection

FLUDARABINE

50mg injection

MERCAPTOPYRINE

50mg tablets

10mg tablets^{SP}

100mg/5ml Suspension

Key to abbreviations

O	Licensed preparation being used for an unlicensed indication
P	Preparation is only included in the Paediatric Formulary and is not included in the GGC Adult Formulary
SP	Available as an unlicensed or special preparation

METHOTREXATE

2.5mg, 10mg tablets

When dispensing is to be carried out in primary care, the 2.5mg strength tablet should be used where possible.

5mg/2ml, 1000mg/10ml, 2000mg injection

10mg/5ml Suspension^{SP}**TIOGUANINE**

40mg tablets

10mg capsules^{SP}50mg/5ml Suspension^{SP}

8.1.4. Vinca alkaloids and etoposide

ETOPOSIDE

100mg/5ml injection

VINBLASTINE

10mg injection

VINCRIStINE

1mg/1ml, 2mg/2ml injection

8.1.5. Other antineoplastic drugs

AMSACRINE

50mg/ml (1.5ml) injection

ARSENIC TRIOXIDE

1mg/ml injection

ASPARAGINASE10,000 unit infusion (Spectrila[®])10,000 unit injection (Erwinase[®])5,000 unit injection (Medac[®] asparinase)Pegylated asparaginase 3,750 unit injection^{SP}**BLINATUMOMAB**

Restricted to use in accordance with regional/national protocol as monotherapy for the treatment of paediatric patients aged 1 year or older with Philadelphia chromosome negative CD19 positive B-cell precursor acute lymphoblastic leukaemia which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic hematopoietic stem cell transplantation.

CARBOPLATIN

50mg, 150mg, 450mg injection

CISPLATIN

10mg, 50mg injection

DASATINIB

Restricted to specialist use in accordance with regional/national protocol for the treatment of paediatric patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukaemia in chronic phase (Ph+ CML-CP) or Ph+ CML-CP resistant or intolerant to prior therapy including imatinib.

DINUTUXIMAB BETA (QARZIBA[®])

4.5mg/ml infusion

Restricted to specialist use only in accordance with national protocols

DECARBAZINE

100mg, 500mg injection

IMATINIB

100mg tablets

The treatment of paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy is not recommended for use in NHS Scotland by the SMC and is non-Formulary.

IPILIMUMAB (YERVOY[®])

5mg/ml infusion

Use as monotherapy for the treatment of advanced (unresectable or metastatic) melanoma in adolescents 12 years and older is restricted to specialist use in accordance with national protocols.

PROCARBAZINE

50mg capsules

TEMOZOLOMIDE

5mg, 20mg, 100mg capsules

TRETINOIN

10mg capsules

Key to abbreviations

O	Licensed preparation being used for an unlicensed indication
P	Preparation is only included in the Paediatric Formulary and is not included in the GGC Adult Formulary
SP	Available as an unlicensed or special preparation

8.2. DRUGS AFFECTING THE IMMUNE RESPONSE

Many of the medicines in this section may also be included in other sections of the Formulary, particular sections 1.5.3 and 10.1.3.

8.2.1. Antiproliferative immunosuppressants**AZATHIOPRINE**

25mg, 50mg tablets
50mg injection

MYCOPHENOLATE MOFETIL

250mg capsules
1g/5ml oral suspension

8.2.2. Corticosteroids and other immunosuppressants**CICLOSPORIN**

10mg, 25mg, 50mg, 100mg capsules
100mg/ml liquid
50mg/ml injection

SIROLIMUS

0.5mg, 1mg tablets
1mg/ml oral solution

TACROLIMUS

0.5mg, 1mg, 5mg immediate-release capsules
200microgram, 1mg granules (as sachets)
Suspension^{SP}

8.2.3. Rituximab and alemtuzumab**ALEMTUZUMAB^O**

30mg/ml concentrate of IV infusion. Specialist use only.
Use in patients <17 years of age is unlicensed

RITUXIMAB

100mg injection. Specialist use only.

8.2.4. Other immunomodulating drugs

No preparations are included in the Formulary

8.3. SEX HORMONES AND HORMONES ANTAGONISTS IN MALIGNANT DISEASE**8.3.1. Oestrogens**

No preparations are included in the Formulary

8.3.2. Progestogens

No preparations are included in the Formulary

8.3.3. Androgens

No preparations are included in the Formulary

8.3.4. Hormone antagonists

See section 6.4

9. NUTRITION AND BLOOD

9.1. ANAEMIAS AND SOME OTHER BLOOD DISORDERS

9.1.1. Iron deficiency anaemias

Oral iron

FERROUS FUMARATE

210mg tablets. (contains 68mg iron)

140mg/5ml syrup (contains 45mg iron in 5ml)

FERROUS SULPHATE

200mg tablets (contains 65mg iron)

SODIUM FEREDETATE

190mg/5ml elixir (contains 27.5mg iron in 5ml)

Parenteral iron

IRON SUCROSE

100mg/5ml injection (Venofer®)

9.1.2. Drugs used in megaloblastic anaemias

Also seen folic acid in section 8.1

FOLIC ACID

5mg tablets

2.5mg/5ml syrup

HYDROXOCOBALAMIN

1mg/1ml injection

9.1.3. Drugs used in hypoplastic, haemolytic, and renal anaemias

EPOETIN BETA

500units, 1000units, 2000units injection

DEFERASIROX

125mg, 250mg, 500mg dispersible tablets

Restricted to patients with myelodysplastic syndrome with an International Prognostic Scoring System (IPSS) score of low or intermediate -1 risk.

DEFERRIOXAMINE MESILATE

500mg injection

9.1.4. Drugs used in platelet disorders

ELTROMBOPAG

25mg tablets

Restricted to use in patients of 1 year or older with severe symptomatic ITP or a higher risk of bleeding.

ROMIPLOSTIM

125microgram, 250microgram, 500 microgram injection

Use for chronic immune (idiopathic) thrombocytopenic purpura (ITP) in patients one year of age and older who are refractory to other treatments is restricted to specialise use in patients with severe symptomatic ITP or patients with a high risk of bleeding.

9.1.5. G6PD deficiency

No preparations are included in the Formulary

9.1.6. Drugs used in neutropenia

LENOGRASTIM

105microgram, 263microgram injection

9.2. FLUIDS AND ELECTROLYTES**9.2.1. Oral preparations for fluid and electrolyte imbalance**

Oral potassium

POTASSIUM CHLORIDEEffervescent tablets (Sando-K®) 12mmol of K⁺ per tablet600mg MR tablets (Slow-K®) 8mmol of K⁺ per tablet

5mmol/5ml syrup (Kay-Cee-L®)

Management of hyperkalaemia

CALCIUM RESONIUM®**RESONIUM A®**

Oral sodium

SODIUM CHLORIDE600mg MR tablets (Slow Sodium®) 10mmol Na⁺ per tablet

Oral rehydration salts

DIORALYTE®

Oral powder

Oral bicarbonate

SODIUM BICARBONATE500mg capsules, 6mmol of HCO₃⁻ per tablet.8.4% (1mmol/ml) Oral solution^{SP}**9.2.2. Parenteral preparations for fluid and electrolyte imbalance**

Electrolytes and water

GLUCOSE 5%

50ml, 100ml, 250ml, 500ml, 1000ml

PLASMA-LYTE® 148

500ml

1000ml

PLASMA-LYTE® 148 WITH GLUCOSE 5%

500ml

1000ml

HALF-STRENGTH RINGER-LACTATE IN**GLUCOSE 5%**

500ml

SODIUM CHLORIDE 0.45%

500ml

SODIUM CHLORIDE 0.9%

50ml, 100ml, 250ml, 500ml, 1000ml

SODIUM CHLORIDE 0.9% WITH**POTASSIUM CHLORIDE 0.3%**500ml contains 20mmol of K⁺**GLUCOSE 5% & SODIUM CHLORIDE 0.45%**

500ml

GLUCOSE 5% & SODIUM CHLORIDE 0.45% WITH POTASSIUM CHLORIDE 0.15%500ml contains 10mmol of K⁺**GLUCOSE 5% & SODIUM CHLORIDE 0.45% WITH POTASSIUM CHLORIDE 0.3%**500ml contains 20mmol of K⁺**GLUCOSE 5% WITH POTASSIUM CHLORIDE 0.3%**500ml contains 20mmol of K⁺**GLUCOSE 10%**

500ml, 1000ml

GLUCOSE 10% & SODIUM CHLORIDE 0.18%

500ml

POTASSIUM CHLORIDE 15% INJECTION (CONC)

10ml. CAUTION: Controlled preparation. Potassium Chloride 15% injection is a concentrated potassium injection that is subject to close control on use in light of risks of inadvertent use and errors. Ready-made infusion bags should be used in preference wherever possible.

SODIUM BICARBONATE 8.4%

250ml

Key to abbreviations

O	Licensed preparation being used for an unlicensed indication
P	Preparation is only included in the Paediatric Formulary and is not included in the GGC Adult Formulary
SP	Available as an unlicensed or special preparation

WATER FOR INJECTION

Plasma substitutes

GELOFUSINE®

500ml

HUMAN ALBUMIN**9.3. INTRAVENOUS NUTRITION**

Intravenous nutrition should only be initiated following advice from pharmacy or an experienced clinician.

9.4. ORAL NUTRITION**9.4.1. Foods for special diets****GLUTAMINE****FRUCTOOLIGOSACCHARIDE****9.4.2. Enteral nutrition**

No preparations are included in the Formulary

9.5. MINERALS**9.5.1. Calcium and magnesium****CALCIUM GLUCONATE**

10% injection, 10ml (equivalent to 2.26mmol in 10ml)

CALCIUM CHLORIDE

10% injection 10ml (equivalent to 6.8mmol in 10ml)

CALCIUM-SANDOZ®

Syrup contains 108.3mg of calcium per 5ml (equivalent to 2.7mmol in 5ml)

SANDOCAL® 400

Effervescent tablets each containing 400mg of calcium (equivalent to 10mmol per tablet)

SANDOCAL® 1000

Effervescent tablets each containing 1000mg of calcium (equivalent to 25mmol per tablet)

CALCICHEW®

Contain calcium 500mg per tablet (equivalent to 12.5mmol per tablet)

CO-MAGALDROX

195/220 Suspension.

Brands include Maalox® and Mucogel®

MAGNESIUM CITRATE6mmol tablets (Magasorb)^U**MAGNESIUM L-ASPARTATE**5mmol sachets ^U

10mmol sachets (Magnasparte)

MAGNESIUM SULPHATE50% injection, contains approximately 2mmol of Mg²⁺ per ml**9.5.2. Phosphorous****PHOSPHATE-SANDOZ®**

Each tablet contains 16.1mmol of phosphate

POTASSIUM ACID PHOSPHATE

13.6% oral solution (equivalent to 1mmol/ml phosphate)

13.6% injection (equivalent to 1mmol/ml phosphate)

CALCIUM CARBONATE^{SP}

250mg dispersible tablets for use as a phosphate-binder

CALCIUM ACETATE

1g tablets (Phosex) for use as a phosphate binder

SEVELAMER HYDROCHLORIDE

800mg tablets for use as a phosphate binder

SEVELAMER CARBONATE

2.4g sachets for use as a phosphate binder

9.5.3. Fluoride

No preparations are included in the Formulary

Key to abbreviations

O	Licensed preparation being used for an unlicensed indication
P	Preparation is only included in the Paediatric Formulary and is not included in the GGC Adult Formulary
SP	Available as an unlicensed or special preparation

- 9.5.4. Zinc
ZINC SULPHATE
 125mg effervescent tablets(Solvazinc®)
-
- 9.6. **VITAMINS**
- 9.6.1. Vitamin A
 100,000units/2ml injection^{SP}
 150,000units/ml oral drops^{SP}
- 9.6.2. Vitamin B group
PYRIDOXINE
 50mg tablets
 50mg/2ml injection^{SP}
THIAMINE
 50mg tablets
 100mg/2ml injection^{SP}
- 9.6.3. Vitamin C
ASCORBIC ACID
 50mg, 200mg tablets
- 9.6.4. Vitamin D
ALFACALCIDOL
 0.25microgram, 1microgram capsules
 2microgram/ml liquid
CALCICHEW-D₃®
 Contains 500mg calcium and 200units of colecalciferol per tablet
COLECALCIFEROL
 Thorens 10,000 units/ml oral drops, solution (200 units per drop)
- 9.6.5. Vitamin E
ALPHA TOCOPHERYL ACETATE
 50mg tablets
 500mg/5ml suspension
 100mg injection^{SP}
- 9.6.6. Vitamin K
PHYTOMENADIONE
 1mg capsules (restricted to use in prevention of neonatal haemorrhagic disease where IM treatment is not applicable)
 1mg/0.5ml neonatal injection
 10mg/ml injection (Konakion® MM Paediatric)
MENADIOL
 10mg tablets^{SP}
- 9.6.7. Multivitamin preparations
VITAMINS CAPSULES BPC
DALIVIT®
 Oral drops.
FORCEVAL®
 Adult and Junior Capsules
KETOVITE®
 Available as tablets and liquid
PARAVIT CF®
 Available as liquid
 Restricted to specialist initiation only for patients with cystic fibrosis

-
- 9.7. **BITTERS AND TONICS**
 No preparations are included in the Formulary

Key to abbreviations

- O Licensed preparation being used for an unlicensed indication
 P Preparation is only included in the Paediatric Formulary and is not included in the GGC Adult Formulary
 SP Available as an unlicensed or special preparation

9.8. METABOLIC DISORDERS**9.8.1. Drugs used in metabolic disorders****ARGININE (L-ARGININE)**

500mg/ml and 600mg/ml injection
100mg/ml oral solution
500mg capsules

BETAINE

Anhydrous powder (Cystadane®)
500mg/ml powder for oral solution^{SP}

BIOTIN (VITAMIN H)^{SP}

5mg tablets

CARGLUMIC ACID (CARBAMYL GLUTAMATE)

200mg dispersible tablets

CARNITINE (LEVOCARNITINE)

300mg/ml oral solution
200mg/ml injection

GLYCEROL

1.1g/ml oral solution Use as adjunctive therapy for chronic management of adults with urea cycle disorders (UCDs) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone is restricted to specialist initiation.

GLYCINE

500mg tablet^{SP}

MERCAPTAMINE (CYSTEAMINE)

50mg, 100mg capsules
0.55% eye drops

Note: Mercaptamine 25mg and 75mg capsules (Procysbi®) are not recommended for use by the SMC and are Non-formulary for treatment of proven nephropathic cystinosis.

NITISINONE (NTBC)

2mg, 5mg, 10mg capsules

SODIUM BENZOATE

500mg tablets
100mg/ml oral solution^{SP}
20% injection

SODIUM DICHLOROACETATE

50mg/ml oral solution^{SP}

SODIUM PHENYLBUTYRATE

500mg tablets
940mg/1g granules (Ammonaps® granules)
483mg/1g granules (Pheburane®)

Note: Granule formulations are not dose equivalent and are not interchangeable and should be prescribed by brand name to avoid confusion.

200mg/ml injection^{SP}

UBIDECARENONE (CO-ENZYME Q10, UBIQUINONE)^{SP}

30mg, 120mg capsules
Used primarily for mitochondrial disorders

9.8.2. Acute porphyrias

No preparations are included in the Formulary

10. MUSCULOSKELETAL AND JOINT DISEASES**10.1. DRUGS USED IN RHEUMATIC DISEASES**

Many of the medicines listed in this section, for example corticosteroids and immunomodulating drugs will also be included for other indications else where in the formulary, for example sections 1.5.3 and 8.1.

10.1.1. Non-steroidal anti-inflammatory drugs**ASPIRIN**

300mg dispersible tablets

DICLOFENAC

25mg, 50mg enteric-coated tablets

50mg dispersible tablets

75mg/3ml injection

12.5mg, 25mg, 50mg, 100mg suppositories

50mg/5ml suspension^{SP}

IBUPROFEN

200mg tablets

100mg/5ml suspension

INDOMETACIN (INDOMETHACIN)

25mg capsules

25mg/5ml suspension^{SP}

NAPROXEN

250mg tablets

PIROXICAM

10mg dispersible tablets

10.1.2. Corticosteroids**DEXAMETHASONE**

10mg/2ml injection

METHYLPREDNISOLONE ACETATE

40mg/ml injection

TRIAMCINOLONE HEXACETONIDE

10mg/ml, 20mg/ml and 40mg/ml injection (for intra-articular or intramuscular injection)

10.1.3. Drugs that suppress the rheumatic disease process**ABATACEPT**

250mg infusion.

125mg sub-cutaneous injection

Specialist use only. Use in combination with methotrexate for the treatment of moderate to severe active polyarticular juvenile idiopathic arthritis in patients aged 6 years who have had an insufficient response to other DMARDs including at least one tumour necrosis factor (TNF) inhibitor is restricted to specialists working within paediatric rheumatology.

ADALIMUMAB

40mg/0.8ml pre-filled injection.

Specialist use only. Use in the treatment of active polyarticular juvenile idiopathic arthritis in children and adolescents aged 2 to 17 years who have had an inadequate response to one or more DMARDs, is restricted to specialists working within paediatric rheumatology. Combination treatment with methotrexate is the primary option.

Use for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy is restricted to specialist rheumatology services (including those working within the network for paediatric rheumatology).

ANAKINRA

100mg/0.67ml pre-filled injection.

Specialist use only. In adolescents, children and infants aged 8 months or older with a body weight of 10kg or above for the treatment of Still's Disease, including Systemic Juvenile Idiopathic Arthritis (SJIA), with active systemic features of moderate to high disease activity, or in patients with continued disease activity after treatment with NSAIDs or glucocorticoids. Anakinra can be given as monotherapy or in combination with other DMARDs.

CHLOROQUINE

50mg/ml syrup

CICLOSPORIN

10mg, 25mg, 50mg, 100mg capsules

100mg/ml liquid

50mg/ml injection

Key to abbreviations

O	Licensed preparation being used for an unlicensed indication
P	Preparation is only included in the Paediatric Formulary and is not included in the GGC Adult Formulary
SP	Available as an unlicensed or special preparation

ETANERCEPT

25mg injection.

Specialist use only. Restricted to specialists working within paediatric rheumatology (including those working within the network for paediatric rheumatology) for the following indications:

- active polyarticular juvenile idiopathic arthritis in children and adolescents from the age of 2 years who have had an inadequate response to, or who have proved intolerant of, methotrexate
- psoriatic arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, methotrexate;
- enthesitis-related arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, conventional therapy.

HYDROXYCHLOROQUINE SULPHATE

200mg tablets

METHOTREXATE

2.5mg, 10mg tablets

When dispensing is to be carried out in primary care, the 2.5mg strength tablet should be used where possible.

5mg/2ml injection

PENICILLAMINE

125mg tablets

SULFASALAZINE (SULPHASALAZINE)

500mg tablets

250mg/5ml suspension

TOCILIZUMAB

20mg/ml concentrate for infusion.

Specialist use only. Use in the treatment of active systemic juvenile idiopathic arthritis in children and adolescents from the age of 2 years who have had an inadequate response to NSAIDs and systemic corticosteroids or previous therapy with methotrexate, is restricted to specialists working within paediatric rheumatology. Monotherapy is accepted use in case of intolerance to methotrexate or where continued treatment with methotrexate is inappropriate.

10.1.4. Cytotoxic-induced hyperuricaemia

ALLOPURINOL

100mg tablets

RASBURICASE

1.5mg, 7.5mg injection

10.1.5. Other drugs for rheumatic diseases

No preparations are included in the Formulary

10.2. DRUGS USED IN NEUROMUSCULAR DISORDERS

10.2.1. Drugs that enhance neuromuscular transmission

EDROPHONIUM CHLORIDE

10mg/ml injection

DISTIGMINE BROMIDE

500microgram/ml injection

NEOSTIGMINE

2.5mg/ml injection

PYRIDOSTIGMINE

60mg tablets

10.2.2. Skeletal muscle relaxants

BACLOFEN

10mg tablets

5mg/5ml liquid

DANTROLENE SODIUM

25mg capsules

DIAZEPAM

2mg, 5mg tablets

2mg/5ml suspension

10mg/2ml injection

10mg/2ml emulsion injection

Key to abbreviations

- O Licensed preparation being used for an unlicensed indication
 P Preparation is only included in the Paediatric Formulary and is not included in the GGC Adult Formulary
 SP Available as an unlicensed or special preparation

10.2.3. Drugs for other neuromuscular disorders

NUSINERSEN

Intrathecal injection

Restricted to specialist use only in patients with symptomatic type 1 (infantile onset) spinal muscular atrophy (SMA).

10.3. **DRUGS FOR THE RELIEF OF SOFT-TISSUE INFLAMMATION**

10.3.1. Enzymes

HYALURONIDASE

1500 unit injection

10.3.2. Rubefacients and other topical antirheumatics

KAOLIN POULTICE

11. EYE

Prescribers should be aware that single-dose preparations of eye drops should only be used in those patients who are unable to tolerate preservatives. Generally, these preparations are much more expensive than regular eye drops.

11.1. ADMINISTRATION OF DRUGS TO THE EYE

Eye preparations are generally available as either eye drops or as eye ointments. The BNF for Children contains useful advice pertaining to the practical use of these preparations. In brief, eye ointments will cause more short-term blurriness due to the nature of their composition than eye drops.

11.2. CONTROL OF MICROBIAL CONTAMINATION

Eye preparations are generally sterile preparations and once opened will only be suitable for use for a short period, the length of which will depend on whether or not preservative is included in the Formulation. When using antibacterial eye preparations to treat infection in both eyes, it is good practice in the acute setting to dispense one pack for each eye labelled clearly to avoid cross-contamination. Again, the BNF for Children contains further advice on this.

11.3. ANTI-INFECTIVE EYE PREPARATIONS**11.3.1. Antibacterials****CHLORAMPHENICOL**

- 0.5% eye drops
- 1% eye ointment
- 0.5% preservative-free single dose units

FUSIDIC ACID

- 1% eye drops

GENTAMICIN

- 0.3% drops for eye or ear

NEOMYCIN SULPHATE

- 0.5% eye drops
- 0.5% eye ointment

OFLOXACIN

- 0.3% eye drops

11.3.2. Antifungals

No preparations are included in the Formulary

11.3.3. Antivirals**ACICLOVIR**

- 3% eye ointment

11.4. CORTICOSTEROIDS AND OTHER ANTI-INFLAMMATORY PREPARATIONS**11.4.1. Corticosteroids****BETAMETHASONE**

- 0.1% drops for eye, ear or nose
- 0.1% eye ointment

DEXAMETHASONE

- 0.1% eye drops

PREDNISOLONE

- 0.5% drops for eye or ear (Predsol®)
- 1% eye drops (Predsol Forte®)

11.4.2. Other anti-inflammatory preparations**OTRIVINE-ANTISTIN®**

- Eye drops

SODIUM CROMOGLICATE

- 2% eye drops

11.5. MYDRIATICS AND CYCLOPLEGICS**ATROPINE**

- 0.5% eye drops
- 1% eye drops
- 1% preservative-free single dose unit (Minims®)

CYCLOPENTOLATE

- 0.5% eye drops
- 1% preservative-free single dose units (Minims®)

PHENYLEPHRINE

- 2.5% preservative-free single dose units (Minims®)
- 10% preservative-free single dose units (Minims®)

TROPICAMIDE

- 0.5% preservative-free single dose units (Minims®)
- 1% preservative-free single dose units (Minims®)

11.6. TREATMENT OF GLAUCOMA**ACETAZOLAMIDE**

- 250mg tablets
- 500mg injection

PILOCARPINE

- 1% eye drops

TIMOLOL

- 0.25% eye drops
- 0.5% eye drops

TRAVOPROST

- 40 micrograms/ml eye drops
- Restricted to specialist initiation

11.7. LOCAL ANAESTHETICS**TETRACAINE (AMETHOCAINE)**

- 0.5% preservative-free single dose units (Minims®)

OXYBUPROCAINE (BENOXINATE)

- 0.4% preservative-free single dose units (Minims®)

PROXYMETACAINE

- 0.5% preservative-free single dose units (Minims®)

11.8. MISCELLANEOUS OPHTHALMIC PREPARATIONS**11.8.1. Tear deficiency, ocular lubricants, and astringents****HYPROMELLOSE**

- 0.3% eye drops

LACRI-LUBE®

- Eye ointment

SIMPLE EYE OINTMENT**SODIUM CHLORIDE (SALINE)**

- 0.9% preservative-free single dose units (Minims®)

CYCLOSPORIN (VERKAZIA®)

- 1mg/ml (0.1%) eye drops
- Restricted to initiation by consultant ophthalmologists for the treatment of severe vernal keratoconjunctivitis (VKC) in children

11.8.2. Ocular diagnostic and peri-operative preparations and photodynamic treatment**DICLOFENAC**

- 0.1% eye drops

FLUORESCEIN SODIUM

- 1% preservative-free single dose units (Minims®)
- 2% preservative-free single dose units (Minims®)

11.9. CONTACT LENSES

- No preparations are included in the Formulary

Key to abbreviations

- O Licensed preparation being used for an unlicensed indication
- P Preparation is only included in the Paediatric Formulary and is not included in the GGC Adult Formulary
- SP Available as an unlicensed or special preparation

12. EAR, NOSE, AND OROPHARYNX**12.1. DRUGS ACTING ON THE EAR****12.1.1. Otitis externa****BETAMETHASONE**

0.1% drops for eye, ear or nose

CIPROFLOXACIN (CETRALAX[®])

2mg/ml ear drop solution

Restricted to clinical situations when off-label or unlicensed ciprofloxacin formulations would otherwise be used.

FLUMETASONE AND CLIQUINOL

Ear drops contains 0.02% flumetasone and 1% clioquinol

GENTAMICIN

0.3% drops for eye or ear

GENTISONE[®] HC

Gentamicin 0.3%, hydrocortisone 1% ear drops

OTOSPORIN[®]

Neomycin 3400units, polymyxin B sulphate 10,000units/ml, hydrocortisone 1% ear drops

PREDNISOLONE0.5% drops for eye or ear (Predsol[®])**SOFRADEX[®]**

Framycetin 0.5%, dexamethasone 0.05%, gramicidin 0.005% drops for ear or eye

OFLOXACIN0.3% eye drops (may be used as eardrops)^o**12.1.2. Otitis media**

No preparations are included in the Formulary.

See section 5.1 for systemic antibacterials which may be used.

12.1.3. Removal of ear wax

No preparations are included in the Formulary.

12.2. DRUGS ACTING ON THE NOSE**12.2.1. Drugs used in nasal allergy****BECLOMETASONE DIPROPIONATE**

50microgram/spray aqueous nasal spray

BETAMETASONE

0.1% nasal drops

MOMETASONE FUROATE

50micrograms/spray nasal spray

12.2.2. Topical nasal decongestants**EPHEDRINE**

0.5%, 1% nasal drops

XYLOMETAZOLINE

0.05%, 0.1% nasal drops

12.2.3. Nasal preparations for infection**MUPIROICIN (BACTROBAN[®])**

2% nasal ointment

NASEPTIN[®]

Chlorhexidine hydrochloride 0.1%, neomycin sulphate 0.5%

12.3. DRUGS ACTING ON THE OROPHARYNX**12.3.1. Drugs for oral ulceration and inflammation****BENZYDAMINE (DIFFLAM[®])**

0.15% oral rinse or 0.15% spray

LIDOCAINE AND CETYLPYRIDINIUM (CALGEL TEETHING GEL[®])*Key to abbreviations*

O	Licensed preparation being used for an unlicensed indication
P	Preparation is only included in the Paediatric Formulary and is not included in the GGC Adult Formulary
SP	Available as an unlicensed or special preparation

12.3.2. Oropharyngeal anti-infective drugs

MICONAZOLE

2% oral gel

NYSTATIN

100,000units/ml oral suspension

12.3.3. Lozenges and sprays

No preparations are included in the Formulary.

12.3.4. Mouthwashes and gargles

CHLORHEXIDINE GLUCONATE

0.2% mouthwash, 1% dental gel

THYMOL

Mouthwash solution-tablets

12.3.5. Treatment of dry mouth

No preparations are included in the Formulary.

13. SKIN**13.1. MANAGEMENT OF SKIN CONDITIONS**

- 13.1.1. Vehicles
 13.1.2. Suitable quantities for prescribing
 13.1.3. Excipients and sensitisation

13.2. EMOLLIENT AND BARRIER PREPARATIONS**13.2.1. Emollients****AQUEOUS CREAM^P**

Used as a soap substitute

DIPROBASE[®]Cream or ointment^P**EMULSIFYING OINTMENT^P****HYDROMOL[®] OINTMENT****LIQUID AND WHITE SOFT PARAFFIN OINTMENT**

Liquid paraffin 50%, white soft paraffin 50%

YELLOW SOFT PARAFFIN^P**13.2.2. Barrier preparations****SIOPEL^{®P}**

Cream

METANIUM^{®P}

Ointment

VASOGEN^{®P}

Cream

ZINC AND CASTOR OIL

Ointment

13.3. TOPICAL ANTIPRURITICS**CALAMINE LOTION****CROTAMITON (EURAX[®])**

10% cream

13.4. TOPICAL CORTICOSTEROIDS**BETAMETASONE DIPROPIONATE**0.05% cream or ointment (Diprosone[®])**BETAMETASONE VALERATE**

0.1% cream or ointment

0.025% cream or ointment (Betnovate-RD[®])**CLOBETASOL PROPIONATE**0.05% cream or ointment (Dermovate[®])**CLOBETASONE BUTYRATE**0.05% cream or ointment (Eumovate[®])**HYDROCORTISONE**

0.5% cream or ointment

1% cream or ointment

MOMETASONE FUROATE0.1% ointment (Elocon[®])

Combinations of steroids and antimicrobials

HYDROCORTISONE AND CLOTRIMAZOLE (CANESTEN HC[®])

1% hydrocortisone and 1% clotrimazole cream

HYDROCORTISONE AND MICONAZOLE NITRATE**(DAKTACORT[®])**

1% hydrocortisone and 2% miconazole cream

HYDROCORTISONE ACETATE AND FUSIDIC ACID**(FUCIDIN H[®])**

1% hydrocortisone acetate and 2% fusidic acid cream

Key to abbreviations

- O Licensed preparation being used for an unlicensed indication
 P Preparation is only included in the Paediatric Formulary and is not included in the GGC Adult Formulary
 SP Available as an unlicensed or special preparation

**BETAMETHASONE VALERATE AND FUSIDIC ACID
(FUCIBET®)**

0.1% betamethasone and 2% fusidic acid cream

CLOBETASONE BUTYRATE, OXYTETRACYCLINE AND NYSTATIN (TRIMOVATE®)

0.05% clobetasone butyrate, 3% oxytetracycline and 100,000 units/g nystatin in a cream

13.5. PREPARATIONS FOR ECZEMA AND PSORIASIS**13.5.1. Preparations for eczema****ZINC AND ICTHAMMOL 1% OINTMENT^{SP}**

Also known as Ichthammol 1% Special Ointment

13.5.2. Preparations for psoriasis**COAL TAR IN YELLOW SOFT PARAFFIN^{SP}**

Available as 1%, 2%, 5% and 10%

DITHRANOL OINTMENT BP

Available in various strengths

DITHRANOL

Available in Yellow Soft Paraffin or Lassar's paste in various strengths

SALICYLIC ACID AND SULPHUR IN YELLOW SOFT PARAFFIN^{SP}

Only to be used when alternative preparations from the NHS GG&C Approved Dermatology Specials list are not appropriate.

SALICYLIC ACID, SULPHUR AND CADE OIL IN YELLOW SOFT PARAFFIN^{SP}

Only to be used when alternative preparations from the NHS GG&C Approved Dermatology Specials list are not appropriate

13.5.3. Drugs affecting the immune response**ADALIMUMAB**

40mg/0.8ml pre-filled injection.

Restricted to specialist use for plaque psoriasis in children and young people in accordance with [NICE TA455](#).

Use for treatment of active moderate to severe hidradenitis suppurativa (HS) (acne inversa) in adolescents from 12 years of age with an inadequate response to conventional systemic HS therapy is restricted to specialist use only.

AZATHIOPRINE

See section 8.2.1

METHOTREXATE

2.5mg, 10mg tablets

When dispensing is to be carried out in primary care, the 2.5mg strength tablet should be used where possible.

ETANERCEPT

10mg, 25mg injection.

Restricted to specialist use for plaque psoriasis in children and young people in accordance with [NICE TA455](#).**USTEKINUMAB**

45mg injection and prefilled syringe

Restricted to specialist use for plaque psoriasis in children and young people in accordance with [NICE TA455](#).**13.6. ACNE AND ROSACEA****13.6.1. Topical preparations**

No preparations are included in the Formulary.

13.6.2. Oral preparations for acne**ISOTRETINOIN**

5mg, 20mg capsules

Restricted to use in hospitals under specialist dermatological supervision

LYMECYCLINE

408mg capsules

13.7. PREPARATIONS FOR WARTS AND CALLUSES**SALACTOL®****SILVER NITRATE^P**

95% caustic pencil

13.8. SUNSCREENS AND CAMOUFLAGERS

13.8.1. Sunscreen preparations

SUNSENSE ULTRA®

This preparation has a protective effect of SPF 60.
ACBS restrictions apply to prescribing in primary care.

13.8.2. Camouflagers

No preparations are included in the Formulary.

13.9. SHAMPOOS AND OTHER PREPARATIONS FOR SCALP CONDITIONS**POLYTAR®**

Please note: contains arachis (peanut) oil

13.10. ANTI-INFECTIVE SKIN PREPARATIONS

13.10.1. Antibacterial preparations

FLAMAZINE®

Silver sulfadiazine 1% cream

FUCIDIN®

Fusidic acid 2% cream or sodium fusidate 2% ointment

MUPIROCIN

2% ointment (Bactroban®)

CHLORAMPHENICOL

1% eye ointment may be applied to wounds (unlicensed use)

POLYMXIN B

Polyfax ointment

13.10.2. Antifungal preparations

CLOTRIMAZOLE

1% cream

MICONAZOLE

Miconazole nitrate 2% cream

NYSTAFORM®

Cream containing nystatin 100,000 units/g and chlorhexidine hydrochloride 1% (Nystaform®)

13.10.3. Antiviral preparations

ACICLOVIR

5% cream

13.10.4. Parasitocidal preparations

DIMETICONE

4% lotion (Hedrin®)

MALATHION

0.5% liquid in aqueous base (Derbac-M®)

PERMETHRIN

5% dermal cream (Lyclear® Dermal Cream)

13.10.5. Preparations for minor cuts and abrasions

MAGNESIUM SULPHATE PASTE BP**INDERMIL®**

Tissue adhesive for use in Emergency Departments only

13.11. SKIN CLEANSERS AND ANTISEPTICS

13.11.1. Alcohols and saline

INDUSTRIAL METHYLATED SPIRITS BP**SODIUM CHLORIDE**

0.9% solution (25ml and 100ml sachets)

Key to abbreviations

O	Licensed preparation being used for an unlicensed indication
P	Preparation is only included in the Paediatric Formulary and is not included in the GGC Adult Formulary
SP	Available as an unlicensed or special preparation

- 13.11.2. Chlorhexidine salts
CHLORHEXIDINE GLUCONATE
 0.5% solution in alcoholic base hand rub
 4% surgical scrub
 0.05% solution (100ml sachets)
- 13.11.3. Cationic surfactants and soaps
CETRIMIDE
 0.15% cetrimide with 0.015% chlorhexadine gluconate
 (Tisept®, Travasept 100®)
- 13.11.4. Iodine
POVIDONE-IODINE
 10% alcoholic tincture (Videne®)
 10% antiseptic solution in an aqueous base (Videne®)
 7.5% surgical scrub in an aqueous base (Videne®)
 2.5% dry powder spray (Betadine®)
- 13.11.5. Phenolics
- 13.11.6. Oxidisers and dyes
HYDROGEN PEROXIDE SOLUTION BP
 6% solution (20 vols)
- 13.11.7. Preparations for promotion of wound healing
 No preparations are included in the Formulary

13.12. ANTIPERSPIRANTS
 No preparations are included in the Formulary

13.13. TOPICAL CIRCULATORY PREPARATIONS
 No preparations are included in the Formulary

14. IMMUNOLOGICAL PRODUCTS AND VACCINES

14.1. ACTIVE IMMUNITY

14.2. PASSIVE IMMUNITY

14.3. STORAGE AND USE

14.4. VACCINES AND ANTISERA

See BNF for Children and The Green Book for guidance relating to vaccines

14.5. IMMUNOGLOBULINS

Human Normal Immunoglobulin is available according to indications identified in the "Clinical Guideline for Immunoglobulin Use" and upon receipt of a completed request. [Click here](#) for more details.

TETANUS IMMUNOGLOBULIN

250units injection (specialist request only)

VARICELLA ZOSTER IMMUNOGLOBULIN

250mg injection (specialist request only)

HEPATITIS IMMUNOGLOBULIN

500units injection (specialist request only)

14.6. INTERNATIONAL TRAVEL

No preparations are included in the Formulary

15. ANAESTHESIA**15.1. GENERAL ANAESTHESIA****15.1.1. Intravenous anaesthetics****ETOMIDATE**

2mg/ml injection (10ml amp)

Restricted to specialist use

KETAMINE

200mg/20ml, 500mg/5ml and 500mg/10ml injection

Restricted to specialist use

PROPOFOL

10mg/ml (1%) injection (emulsion)

Restricted to specialist use

THIOPENTAL SODIUM

500mg injection

Restricted to specialist use

15.1.2. Inhalational anaesthetics**HALOTHANE^{SP,P}**

Restricted to specialist use

ISOFLURANE

Restricted to specialist use

SEVOFLURANE

Restricted to specialist use

DESFLURANE

Restricted to specialist use

NITROUS OXIDE

Restricted to specialist use

EQUANOX[®]

50% nitrous oxide and 50% oxygen

15.1.3. Antimuscarinic drugs**ATROPINE SULPHATE**

400, 600microgram injection

Restricted to specialist use

GLYCOPYRRONIUM BROMIDE

200microgram/ml injection

Restricted to specialist use

HYOSCINE HYDROBROMIDE

400microgram injection

Restricted to specialist use

15.1.4. Sedative and analgesic peri-operative drugs**15.1.4.1. Anxiolytics, neuroleptics and antihistamines****ALIMEMAZINE**

30mg/5ml syrup

Restricted to specialist use only for sedative purposes.

CHLORPROMAZINE

25mg/ml injection

DIAZEPAM

10mg/2ml injection for infusion

10mg/2ml emulsion injection

LORAZEPAM

4mg/ml injection

MIDAZOLAM

2mg/ml injection

PROMETHAZINE HYDROCHLORIDE

25mg/ml injection

TEMAZEPAM

10mg/5ml oral solution

Key to abbreviations

O	Licensed preparation being used for an unlicensed indication
P	Preparation is only included in the Paediatric Formulary and is not included in the GGC Adult Formulary
SP	Available as an unlicensed or special preparation

- 15.1.4.2. Non-opioid analgesics
DICLOFENAC
 75mg/3ml injection
 12.5mg, 25mg, 50mg, 100mg suppositories
- 15.1.4.3. Opioid analgesics
ALFENTANIL
 500microgram/ml injection
FENTANYL
 50microgram/ml injection
MORPHINE SULPHATE
 500microgram/ml injection
 10mg/ml, 15mg/ml, 30mg/ml injection
PETHIDINE HYDROCHLORIDE
 50mg/ml, 100mg/2ml injection
REMIFENTANIL
 1mg injection
- 15.1.5. Neuromuscular blocking drugs
ATRACURIUM BESILATE
 4mg/ml injection
PANCURONIUM BROMIDE
 4mg/2ml injection
ROCURONIUM BROMIDE
 4mg/ml injection
SUXAMETHONIUM CHLORIDE
 100mg/2ml injection
VECURONIUM BROMIDE
 10mg vial
- 15.1.6. Anticholinesterases used in anaesthesia
NEOSTIGMINE METILSULFATE
 2.5mg/ml injection
GLYCOPYRRONIUM-NEOSTIGMINE
 2.5mg neostigmine, 500microgram glycopyrronium
- 15.1.7. Antagonists for central and respiratory depression
DOXAPRAM
 100mg/5ml injection
FLUMAZENIL
 100microgram/ml injection
NALOXONE HYDROCHLORIDE
 40microgram/2ml injection
 400microgram/ml injection
- 15.1.8. Drugs for malignant hyperthermia
DANTROLENE SODIUM
 20mg vial
-
- 15.2. LOCAL ANAESTHESIA
ETHYL CHLORIDE^P
 Spray.
TETRACAINE (AMETHOCAINE)
 4% topical gel
BUPIVACAINE HYDROCHLORIDE
 0.25%, 0.5% injection

BUPIVACAINE AND ADRENALINE
 0.25%, 0.5% bupivacaine with 1 in 200,000 adrenaline

Key to abbreviations

- O Licensed preparation being used for an unlicensed indication
 P Preparation is only included in the Paediatric Formulary and is not included in the GGC Adult Formulary
 SP Available as an unlicensed or special preparation

EMLA®

Lidocaine 2.5%, prilocaine 2.5% topical cream

LIDOCAINE HYDROCHLORIDE

1%, 2% injection

2% topical gel

4% topical solution

4% cream (LMX4 hospital use only)

10% spray

LIDOCAINE WITH ADRENALINE

Lidocaine 1%, 2% with adrenaline 1 in 200,000

APPENDIX 1: EMERGENCY TREATMENT OF POISONING

Advice on the treatment of poisoning is available from the UK National Poisons Information Service (0844 892 0111) or from TOXBASE (www.toxbase.org - username and password required)

ACETYLCYSTEINE

2g in 10ml injection

ACTIVATED CHARCOAL

1.04g/5ml oral suspension (Actidose-Aqua®)

DEFERRIOXAMINE MESILATE

500mg injection

DICOBALT EDETATE

15mg/5ml injection (20ml)

DIMERCAPROL

50mg/ml injection

NALOXONE HYDROCHLORIDE

40microgram/2ml injection

400microgram/ml injection

SODIUM CALCIUM EDETATE

200mg/ml injection